Alexion Pharmaceuticals Inc. Release: European Commission Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Prevention Of Graft Rejection Following Solid Organ Transplantation

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris® (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

Help employers find you! Check out all the jobs and post your resume.